Education
About Us
Working with TipRanks
Follow Us
Jasper Therapeutics (JSPR)
NASDAQ:JSPR
Total Valuation
Jasper Therapeutics has a market cap or net worth of $47.46M. The enterprise value is $47.75M.
Market Cap$47.46M
Enterprise Value$47.75M
Share Statistics
Jasper Therapeutics has 16,253,332 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding16,253,332
Owned by Insiders10.78%
Owned by Institutions41.22%
Financial Efficiency
Jasper Therapeutics’s return on equity (ROE) is -1.16 and return on invested capital (ROIC) is -115.80%.
Return on Equity (ROE)-1.16
Return on Assets (ROA)-0.89
Return on Invested Capital (ROIC)-115.80%
Return on Capital Employed (ROCE)-1.20
Revenue Per Employee0.00
Profits Per Employee-1.11M
Employee Count64
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Jasper Therapeutics is ―. Jasper Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value5.06
Price to FCF―
Price to Operating Cash Flow-0.47
PEG Ratio―
Income Statement
In the last 12 months, Jasper Therapeutics had revenue of 0.00 and earned -71.27M in profits. Earnings per share was -4.89.
Revenue0.00
Gross Profit-1.37M
Operating Income-77.73M
Pretax Income-72.76M
Net Income-71.27M
EBITDA-71.39M
Earnings Per Share (EPS)-4.89
Cash Flow
In the last 12 months, operating cash flow was -95.96M and capital expenditures -377.00K, giving a free cash flow of -96.34M billion.
Operating Cash Flow-95.96M
Free Cash Flow-96.34M
Free Cash Flow per Share-5.93
Dividends & Yields
Jasper Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.66
52-Week Price Change-85.56%
50-Day Moving Average3.69
200-Day Moving Average8.30
Relative Strength Index (RSI)42.40
Average Volume (3m)294.97K
Important Dates
Jasper Therapeutics upcoming earnings date is Nov 6, 2025, After Close (Confirmed).
Last Earnings DateAug 13, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend Date―
Financial Position
Jasper Therapeutics as a current ratio of 4.98, with Debt / Equity ratio of 9.17%
Current Ratio4.98
Quick Ratio4.98
Debt to Market Cap0.00
Net Debt to EBITDA0.98
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Jasper Therapeutics has paid -1.49M in taxes.
Income Tax-1.49M
Effective Tax Rate0.02
Enterprise Valuation
Jasper Therapeutics EV to EBITDA ratio is -3.39, with an EV/FCF ratio of -3.83.
EV to Sales0.00
EV to EBITDA-3.39
EV to Free Cash Flow-3.83
EV to Operating Cash Flow-3.87
Balance Sheet
Jasper Therapeutics has $39.51M in cash and marketable securities with $2.15M in debt, giving a net cash position of -$37.35M billion.
Cash & Marketable Securities$39.51M
Total Debt$2.15M
Net Cash-$37.35M
Net Cash Per Share-$2.30
Tangible Book Value Per Share$4.23
Margins
Gross margin is -41.82%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-41.82%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Jasper Therapeutics is $21.38, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$21.38
Price Target Upside632.19% Upside
Analyst ConsensusModerate Buy
Analyst Count11
Revenue Growth Forecast―
EPS Growth Forecast-17.96%